PGM169/GL67A ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症4

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01621867
(ClinicalTrials.gov)
May 201214/6/2012Repeated Application of Gene Therapy in CF PatientsA Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic FibrosisCystic FibrosisDrug: pGM169/GL67A;Drug: PlaceboImperial College LondonUniversity of Edinburgh;University of Oxford;Royal Brompton & Harefield NHS Foundation TrustCompleted12 YearsN/ABoth130Phase 2United Kingdom
2EUCTR2011-004761-33-GB
(EUCTR)
08/03/201214/12/2011Repeated application of gene therapy in patients with cystic fibrosisA randomised double-blind placebo-controlled Phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis - Repeated application of gene therapy in patients with CF v01-010204 Cystic fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: pGM169/GL67A
Other descriptive name: pGM169/GL67A
Imperial CollegeNULLNot Recruiting Female: yes
Male: yes
130 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
3NCT00789867
(ClinicalTrials.gov)
November 200811/11/2008Single Dose of pGM169/GL67A in CF PatientsEvaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic FibrosisCystic FibrosisDrug: pGM169/GL67AImperial College LondonRoyal Brompton & Harefield NHS Foundation Trust;University of Oxford;University of Edinburgh;Cystic Fibrosis Trust;University of PennsylvaniaCompleted16 Years70 YearsAll35Phase 1/Phase 2United Kingdom
4EUCTR2007-004050-85-GB
(EUCTR)
15/09/200813/10/2008Evaluation of safety and gene expression with a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis - Single dose of pGM169/GL67A in CF patientsEvaluation of safety and gene expression with a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis - Single dose of pGM169/GL67A in CF patients Cystic fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: pGM169/GL67A
Product Code: pGM169/GL67A
Imperial CollegeNULLNot RecruitingFemale: yes
Male: yes
United Kingdom